Virios Therapeutics Inc (VIRI) News

Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

ATLANTA, May 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios...

Form 424B4 - Prospectus [Rule 424(b)(4)]

Form 8-K - Current report

Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

ATLANTA, May 19, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios...

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

ATLANTA, May 17, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios...

Form 424B4 - Prospectus [Rule 424(b)(4)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

- Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring...

Form 8-K - Current report

Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a...

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

- New patent would extend coverage and expand potential value of Virios’ antiviral pipeline globally –...

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]